The  Chairman  Hans  Peter  Bøhn  has  today,  19 September 2018, subscribed for
40,106 new  shares in PCI Biotech Holding  ASA (the "Company") at a subscription
price  of  NOK  30 per  share  by  exercising all his 40,106 subscription rights
allocated  in the  Company's ongoing  rights issue.  After the transaction, Hans
Peter Bøhn will have a total shareholding in the Company of 123,662 shares.

The  boad  member  Lars  Viksmoen  has  today, 19 September 2018, subscribed for
1,920 new  shares in PCI  Biotech Holding ASA  (the "Company") at a subscription
price  of  NOK  30 per  share  by  exercising  all his 1,920 subscription rights
allocated  in  the  Company's  ongoing  rights  issue  through  his wholly owned
company,  Stocken Invest  AS. In  addition, Stocken  Invest AS has bought 1,580
subscription  rights at an average price  of NOK 4.40 per subscription right and
subsequently   exercised  the  1,580 acquired  subscription  rights.  After  the
transactions, Stocken Invest AS will have a total shareholding in the Company of
7,500 shares.  Stocken  Invest  AS  has  previously  entered  into  a  guarantee
agreement  of NOK 1,000,000 in relation to the rights issue, and the exercise of
subscription rights will, in compliance with the guarantee agreement, reduce the
guarantee liability correspondingly.

The  board member Christina Herder  has today, 19 September 2018, subscribed for
1,645 new  shares in PCI  Biotech Holding ASA  (the "Company") at a subscription
price  of NOK  30 per share  by exercising  1,645 of her  allocated subscription
rights  in the  Company's ongoing  rights issue.  In addition,  she has sold her
remaining  2,365 subscription  rights  at  an  average  price  of  NOK  4.40 per
subscription  right.  After the transactions, Christina Herder will have a total
shareholding in the Company of 10,000 shares.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, NO-0379 Oslo.
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757.

This  information is subject to the  disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
